Anaphylaxis to three humanized antibodies for severe asthma: a case study

BACKGROUND: Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. CASE PRESENTATION: We report the case of a 35-year-old woman with severe asthma,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jingo, Koichi, Harada, Norihiro, Nishioki, Toshihiko, Torasawa, Masahiro, Yamada, Tomoko, Asao, Tetsuhiko, Takagi, Haruhi, Takeshige, Tomohito, Ito, Jun, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288423/
https://www.ncbi.nlm.nih.gov/pubmed/32536947
http://dx.doi.org/10.1186/s13223-020-00446-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288423/
https://www.ncbi.nlm.nih.gov/pubmed/32536947
http://dx.doi.org/10.1186/s13223-020-00446-w

Ejemplares similares